Medicare GLP-1 for Men Over 65: The $50 "Bridge," Explained
For years, Medicare flatly would not cover weight-loss drugs. That changes this summer. Starting July 1, 2026, a federal pilot will help cover GLP-1 medications for obesity with copays as low as $50 a month. It's real, it's significant — and it comes with fine print every man over 65 should understand before getting his hopes up.
The Medicare GLP-1 Bridge at a glance
- • What it is: a time-limited Medicare pilot — the "GLP-1 Bridge" — announced by CMS.
- • When: July 1, 2026 through December 31, 2027.
- • Your cost: copays as low as $50/month for eligible Part D beneficiaries.
- • What's covered: the pill and injectable forms of Wegovy, the Zepbound KwikPen, and Lilly's new oral pill Foundayo.
- • The negotiated price: the government's price for the injectables lands around $245/month across doses.
Who qualifies
The pilot is built for Medicare Part D beneficiaries who have obesity and at least one weight-related condition (a comorbidity such as heart disease, high blood pressure, or sleep apnea). It is not an open door for anyone who wants to lose a few pounds — expect your prescriber to document a qualifying diagnosis. If you already see a doctor for weight or a related condition, that conversation is the place to start.
The fine print men over 65 should weigh
This is a bridge, and the name is honest. A few things to keep in mind:
- • It's temporary. The pilot runs about 18 months. Whether a permanent benefit follows in 2028 is not yet decided.
- • Clinical guardrails apply. Coverage is tied to medical criteria, not preference, and the rules can be specific.
- • It's not universal. Plenty of men over 65 won't meet the criteria, and the program can end while you're still on treatment — worth a plan for what happens to your cost in 2028.
None of that makes it a bad deal. For a man who qualifies, $50/month for a medication that has cost well over $1,000 at list price is genuinely life-changing. Just go in with eyes open about the timeline.
If you're under 65 or don't qualify
The cash market has gotten dramatically friendlier. Brand-name self-pay programs now run far below old list prices, and compounded options through licensed telehealth start around $99/month. Two paths depending on what you want:
Want the exact brand-name drugs Medicare's pilot covers? Sesame Care focuses on FDA-approved, brand-name Wegovy and Zepbound — these are the manufacturer's own products, never compounded — with insurance-friendly, transparent pricing.
Want the lowest monthly cost? Compounded semaglutide from a LegitScript-monitored provider is the budget route. Compounded medications are made by licensed pharmacies and are not FDA-approved products, so a licensed clinician should confirm it's right for you.
Sesame CareBRAND-NAME
Brand-name pricingAccess to FDA-approved, brand-name Wegovy and Zepbound with transparent, insurance-friendly pricing — the natural fit if you want the same medications Medicare's pilot covers.
See Options →Paid link
GobyMedsBUDGET
From $99/moIf you're under 65, don't qualify, or want a lower cash price: compounded GLP-1 from $99/mo, LegitScript-certified, free consult and shipping. Code x7X72r saves $25.
Compounded medications are not FDA-approved · Paid link
Yucca Health
Budget GLP-1Straightforward, budget-friendly compounded GLP-1 with a fast signup — a low-cost cash option while you sort out coverage.
Get Started →Compounded medications are not FDA-approved · Paid link
Bridge coverage vs. paying cash: a quick map
| Option | Typical monthly cost | Best for |
|---|---|---|
| Medicare GLP-1 Bridge | ~$50 copay | Part D members with obesity + a comorbidity |
| Brand-name self-pay | ~$199–$499 | Want FDA-approved brand, don't qualify for the pilot |
| Compounded via telehealth | from ~$99 | Lowest cash price (not FDA-approved) |
| Foundayo (oral, self-pay) | from ~$149 | Prefer a daily pill, paying cash |
Prices in this market move constantly as manufacturers, the government, and telehealth providers compete. Treat these as ballpark figures and confirm current pricing before you commit.
How to actually use the benefit
If you think you might qualify, the path is more straightforward than most Medicare paperwork:
- • Confirm you have Part D. The pilot runs through your Part D drug coverage, not Part B.
- • Talk to your prescriber early. You'll need a documented obesity diagnosis plus a qualifying weight-related condition. If you already see a doctor for blood pressure, heart issues, or sleep apnea, raise it there.
- • Ask whether your specific plan is participating and what tier the medication falls under — that's what determines your real copay.
- • Expect prior authorization. Most plans will require it for GLP-1s; your prescriber's office handles the form.
- • If you're denied, ask about the appeal — and have a cash backup in mind so you're not stuck waiting.
Medicare GLP-1 FAQ
Does Medicare cover Ozempic for weight loss?
Ozempic is approved for type 2 diabetes, not weight loss, so it isn't part of the obesity pilot. The Bridge covers the obesity-indicated drugs: Wegovy, Zepbound, and Foundayo. Ozempic may still be covered separately if you have diabetes.
What if I'm on Medicare Advantage?
Advantage plans include Part D drug coverage, so the benefit generally flows through your plan — but details vary, so check your specific plan's formulary.
What happens when the pilot ends in 2028?
That's the open question. The Bridge is funded through December 31, 2027. Whether a permanent benefit follows hasn't been decided, so plan for the possibility your cost changes.
Is $50 the price for everyone?
Copays are described as "as low as" $50 for eligible beneficiaries. Your plan's tier structure and deductible can move the number, so confirm with your plan.
Not sure which path fits?
Check your eligibility in a few minutes and see your real out-of-pocket options — brand-name or compounded, insurance or cash.
Check My Eligibility →Paid link
Medical Disclaimer: This article is for general information only and is not medical advice. Prescription medications require evaluation and ongoing supervision by a licensed clinician. Talk to a qualified healthcare provider about what is appropriate for your individual situation. This is a sensitive area of health — if anything here raises a concern, raise it with your doctor.